Is HRT Safe? The FDA Just Reversed a 20-Year Warning

A single 2002 study scared a generation of women off HRT. Now the FDA has pulled the warning that started it.

On November 10, 2025, the Food and Drug Administration (FDA) announced it would remove the broad “black box” warnings from menopausal hormone replacement therapy (HRT) products containing estrogen or a combination of estrogen and progesterone, in both oral and topical formulations.

The updated labels — being rolled out since early 2026 — reflect the age-specific health benefits of starting HRT, which replenishes ovarian hormones to ease menopausal symptoms, within a decade of the onset of menopause.

Why HRT Carried a Black Box Warning

The black box warning on hormone therapy products was a cautionary label about health risks associated with them, including breast cancer, cardiovascular disease, dementia, and blood clots. It was issued in 2003 after the misleading findings of incomplete data from a Women’s Health Initiative (WHI) study. Black box warnings are considered the strongest cautionary measure for a drug without removing it entirely from the market.

As you might expect, the warning caused a significant drop in the use of HRT. In 1999, over a quarter of menopausal women in the US used HRT. After the warning was issued in 2003, only 16% did. By 2020, it plummeted to only 5%.

What the WHI Study Got Wrong About HRT

In the study, WHI assessed oral conjugated equine estrogens, used to manage early menopausal symptoms like hot flashes and insomnia, taken with and without medroxyprogesterone acetate, a synthetic form of progesterone. But the trial had notable limitations: its participants were all aged 50 to 79 — averaging 63, many of them well past menopause — and a number had underlying risk factors that could skew the results.

As a result, the study failed to identify how the timing of HRT is critical for assessing its benefit-risk balance. Follow-up analyses found more favorable effects — including a significant reduction in all-cause mortality — among women who started HRT under age 60 or within 10 years of menopause, compared with those who began it later.

These findings showed the safety profile of HRT to be acceptable when appropriately timed and effective at managing the symptoms associated with menopause. Moreover, HRT administration has evolved in the past 20 years, as more precise doses are available, as are the means of delivery (e.g., percutaneously).

Is HRT Right for You?

HRT should be managed on an individualized basis under your doctor’s guidance. Age, severity of symptoms, and a history of cardiovascular disease, breast cancer, osteoporosis, and other chronic conditions all influence the specifics of the HRT that would be right for you.